Genzyme Predicts $5 Bil. In Annual Revenues By 2010 From Current Portfolio
This article was originally published in The Pink Sheet Daily
Executive Summary
The firm is anticipating its forthcoming Pompe disease therapy Myozyme to contribute to growth starting in 2006.